Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Gastric cancer in 2012: Defining treatment standards and novel insights into disease biology.

Literature DB >> 23296114

Gastric cancer in 2012: Defining treatment standards and novel insights into disease biology.

Elizabeth C Smyth¹, David Cunningham.

Abstract

Entities: Disease

Mesh：

Substances：
Antineoplastic Agents

Year: 2013 PMID： 23296114 DOI： 10.1038/nrclinonc.2012.228

Source DB: PubMed Journal: Nat Rev Clin Oncol ISSN： 1759-4774 Impact factor: 66.675

× No keyword cloud information.

6 in total

1. Preoperative chemoradiotherapy for esophageal or junctional cancer.

Authors: P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast
Journal: N Engl J Med Date: 2012-05-31 Impact factor: 91.245

2. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors: Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal: Lancet Date: 2010-08-19 Impact factor: 79.321

3. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

Authors: Jung Hun Kang; Soon Il Lee; Do Hyoung Lim; Keon-Woo Park; Sung Yong Oh; Hyuk-Chan Kwon; In Gyu Hwang; Sang-Cheol Lee; Eunmi Nam; Dong Bok Shin; Jeeyun Lee; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Se Hoon Park
Journal: J Clin Oncol Date: 2012-03-12 Impact factor: 44.544

4. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.

Authors: Yung-Jue Bang; Young-Woo Kim; Han-Kwang Yang; Hyun Cheol Chung; Young-Kyu Park; Kyung Hee Lee; Keun-Wook Lee; Yong Ho Kim; Sang-Ik Noh; Jae Yong Cho; Young Jae Mok; Yeul Hong Kim; Jiafu Ji; Ta-Sen Yeh; Peter Button; Florin Sirzén; Sung Hoon Noh
Journal: Lancet Date: 2012-01-07 Impact factor: 79.321

5. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.

Authors: Shinichi Sakuramoto; Mitsuru Sasako; Toshiharu Yamaguchi; Taira Kinoshita; Masashi Fujii; Atsushi Nashimoto; Hiroshi Furukawa; Toshifusa Nakajima; Yasuo Ohashi; Hiroshi Imamura; Masayuki Higashino; Yoshitaka Yamamura; Akira Kurita; Kuniyoshi Arai
Journal: N Engl J Med Date: 2007-11-01 Impact factor: 91.245

6. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.

Authors: Niantao Deng; Liang Kee Goh; Hannah Wang; Kakoli Das; Jiong Tao; Iain Beehuat Tan; Shenli Zhang; Minghui Lee; Jeanie Wu; Kiat Hon Lim; Zhengdeng Lei; Glenn Goh; Qing-Yan Lim; Angie Lay-Keng Tan; Dianne Yu Sin Poh; Sudep Riahi; Sandra Bell; Michael M Shi; Ronald Linnartz; Feng Zhu; Khay Guan Yeoh; Han Chong Toh; Wei Peng Yong; Hyun Cheol Cheong; Sun Young Rha; Alex Boussioutas; Heike Grabsch; Steve Rozen; Patrick Tan
Journal: Gut Date: 2012-02-07 Impact factor: 23.059

6 in total

21 in total

1. FBXL5 targets cortactin for ubiquitination-mediated destruction to regulate gastric cancer cell migration.

Authors: Gang Cen; Hong-Hua Ding; Bin Liu; Wei-Dong Wu
Journal: Tumour Biol Date: 2014-05-28

2. Decreased expression of serum miR-647 is associated with poor prognosis in gastric cancer.

Authors: Huan Ma; Peijun Wang; Yuan Li; Yan Yang; Shuhui Zhan; Yuqiang Gao
Journal: Int J Clin Exp Pathol Date: 2019-07-01

3. Clinical significance of various growth factors in patients with different gastric neoplasms.

Authors: Lidia Kędzierska; Anna Madej-Michniewicz; Natalia Marczuk; Barbara Dołęgowska; Teresa Starzyńska; Wojciech Błogowski
Journal: Am J Transl Res Date: 2020-01-15 Impact factor: 4.060

4. ASB16-AS1 up-regulated and phosphorylated TRIM37 to activate NF-κB pathway and promote proliferation, stemness, and cisplatin resistance of gastric cancer.

Authors: Tao Fu; Ke Ji; Li Jin; Ji Zhang; Xiaojiang Wu; Xin Ji; Biao Fan; Ziyu Jia; Anqiang Wang; Jiaen Liu; Zhaode Bu; Jiafu Ji
Journal: Gastric Cancer Date: 2020-06-22 Impact factor: 7.370

5. Artemisinin inhibits gastric cancer cell proliferation through upregulation of p53.

Authors: Hong-Tao Zhang; Yun-Long Wang; Jie Zhang; Qin-Xian Zhang
Journal: Tumour Biol Date: 2014-02

6. MicroRNA-96 expression induced by low-dose cisplatin or doxorubicin regulates chemosensitivity, cell death and proliferation in gastric cancer SGC7901 cells by targeting FOXO1.

Authors: Chunhui Lang; Miao Xu; Ziyi Zhao; Jinyao Chen; Lishi Zhang
Journal: Oncol Lett Date: 2018-07-11 Impact factor: 2.967

7. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.

Authors: Siraj M Ali; Eric M Sanford; Samuel J Klempner; Douglas A Rubinson; Kai Wang; Norma A Palma; Juliann Chmielecki; Roman Yelensky; Gary A Palmer; Deborah Morosini; Doron Lipson; Daniel V Catenacci; Fadi Braiteh; Rachel Erlich; Philip J Stephens; Jeffrey S Ross; Sai-Hong Ignatius Ou; Vincent A Miller
Journal: Oncologist Date: 2015-04-16